Literature DB >> 15472839

Nasopharyngeal pneumococcal carriage after combined pneumococcal conjugate and polysaccharide vaccination in children with a history of recurrent acute otitis media.

Reinier H Veenhoven1, Debby Bogaert, Anne G M Schilder, Ger T Rijkers, Cuno S P M Uiterwaal, Herma H Kiezebrink, Muriel J P van Kempen, Inge J Dhooge, Jacob Bruin, Ed P F Ijzerman, Ronald de Groot, Wietse Kuis, Peter W M Hermans, Elisabeth A M Sanders.   

Abstract

BACKGROUND: We recently showed that vaccination with a 7-valent pneumococcal conjugate vaccine (PCV7) followed by a 23-valent pneumococcal polysaccharide vaccine (PPSV23) failed to prevent new episodes of acute otitis media (AOM) in previously unvaccinated toddlers and children with a history of recurrent AOM. We describe in detail the impact of pneumococcal vaccinations on nasopharyngeal carriage of S. pneumoniae in this study population.
METHODS: The impact of vaccination with PCV7 followed by PPSV23 on pneumococcal nasopharyngeal carriage was studied in a prospective, randomized trial involving 383 children (age range, 1-7 years) with previous AOM. Nasopharyngeal swab specimens were collected at the time of first vaccination and at 6-7-month intervals during the 26-month follow-up period.
RESULTS: Overall, pneumococcal carriage rates did not diminish, remaining at approximately 50% in both PCV7/PPSV23 and control vaccinees. A significant shift from conjugate vaccine- to nonconjugate vaccine-type pneumococci was observed in children aged 1-2 years, who received the conjugate vaccine twice before the polysaccharide vaccine was administered. Conjugate vaccine serotype carriage was not influenced in older children, who received the conjugate vaccine once before receiving the polysaccharide booster.
CONCLUSIONS: The administration of conjugate vaccines at least twice also after 2 years of age may be mandatory for reducing the carriage of conjugate vaccine serotypes in children with recurrent AOM. Polysaccharide booster vaccination did not affect nasopharyngeal colonization with serotypes not included in the conjugate vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15472839     DOI: 10.1086/422651

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  15 in total

1.  Pneumococcal nasopharyngeal carriage following reduced doses of a 7-valent pneumococcal conjugate vaccine and a 23-valent pneumococcal polysaccharide vaccine booster.

Authors:  F M Russell; J R Carapetis; C Satzke; L Tikoduadua; L Waqatakirewa; R Chandra; A Seduadua; S Oftadeh; Y B Cheung; G L Gilbert; E K Mulholland
Journal:  Clin Vaccine Immunol       Date:  2010-10-13

2.  Natural antibodies against several pneumococcal virulence proteins in children during the pre-pneumococcal-vaccine era: the generation R study.

Authors:  Ankie Lebon; Nelianne J Verkaik; Joost A M Labout; Corné P de Vogel; Herbert Hooijkaas; Henri A Verbrugh; Willem J B van Wamel; Vincent W V Jaddoe; Albert Hofman; Peter W M Hermans; Jiangtao Ma; Tim J Mitchell; Henriette A Moll; Alex van Belkum
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

3.  Pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccine; immunogenicity in patients with ataxia-telangiectasia.

Authors:  A Stray-Pedersen; I S Aaberge; A Früh; T G Abrahamsen
Journal:  Clin Exp Immunol       Date:  2005-06       Impact factor: 4.330

4.  Concomitant administration of Mycobacterium bovis BCG with the meningococcal C conjugate vaccine to neonatal mice enhances antibody response and protective efficacy.

Authors:  Siggeir F Brynjolfsson; Stefania P Bjarnarson; Elena Mori; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

5.  Safety and immunogenicity of the 23-valent pneumococcal polysaccharide vaccine at 12 months of age, following one, two, or three doses of the 7-valent pneumococcal conjugate vaccine in infancy.

Authors:  F M Russell; P V Licciardi; A Balloch; V Biaukula; L Tikoduadua; J R Carapetis; J Nelson; A W J Jenney; L Waqatakirewa; S Colquhoun; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-01       Impact factor: 3.641

6.  [Silent mastoiditis in a 5-month-old infant].

Authors:  N B Gassmann; T Linder
Journal:  HNO       Date:  2006-11       Impact factor: 1.284

7.  Long-term impact of pneumococcal polysaccharide vaccination on nasopharyngeal carriage in children previously vaccinated with various pneumococcal conjugate vaccine regimes.

Authors:  Laura K Boelsen; Eileen M Dunne; Karen E Lamb; Kathryn Bright; Yin Bun Cheung; Lisi Tikoduadua; Fiona M Russell; E Kim Mulholland; Paul V Licciardi; Catherine Satzke
Journal:  Vaccine       Date:  2015-07-29       Impact factor: 3.641

8.  High serological response to pneumococcal vaccine in nephrotic children at disease onset on high-dose prednisone.

Authors:  Tim Ulinski; Sandrine Leroy; Marie Dubrel; Sylvie Danon; Albert Bensman
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

9.  Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial.

Authors:  Elske J M van Gils; Eelko Hak; Reinier H Veenhoven; Gerwin D Rodenburg; Debby Bogaert; Jacob P Bruin; Loek van Alphen; Elisabeth A M Sanders
Journal:  PLoS One       Date:  2011-06-10       Impact factor: 3.240

Review 10.  Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective.

Authors:  Catherine Weil-Olivier; Mark van der Linden; Iris de Schutter; Ron Dagan; Lorenzo Mantovani
Journal:  BMC Infect Dis       Date:  2012-09-07       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.